New study aims to shield blood cancer patients from Post-CAR-T infections

NCT ID NCT05952804

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tests whether giving antibody replacement therapy can reduce serious infections in people who have received CAR-T cell therapy for blood cancers. CAR-T therapy often lowers the body's natural antibodies, raising infection risk. The trial will compare the antibody treatment to a placebo in 150 patients to see if it helps prevent bacterial infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

City of Hope Cancer Center
RECRUITING

Duarte, California, 91010, United States
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Oregon Health and Science University (OHSU) Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.